We are live on ! Find out more
ALDX icon

Aldeyra Therapeutics

115 hedge funds and large institutions have $147M invested in Aldeyra Therapeutics in 2021 Q4 according to their latest regulatory filings, with 21 funds opening new positions, 39 increasing their positions, 34 reducing their positions, and 23 closing their positions.

New
Increased
Maintained
Reduced
Closed

81% more call options, than puts

Call options by funds: $8.67M | Put options by funds: $4.79M

15% more repeat investments, than reductions

Existing positions increased: 39 | Existing positions reduced: 34

9% less first-time investments, than exits

New positions opened: 21 | Existing positions closed: 23

2% less funds holding

Funds holding: 117115 (-2)

5.83% less ownership

Funds ownership: 68.69%62.85% (-5.8%)

58% less capital invested

Capital invested by funds: $349M → $147M (-$202M)

75% less funds holding in top 10

Funds holding in top 10: 41 (-3)

Holders
115
Holders Change
-2
Holders Change %
-1.71%
% of All Funds
1.77%
Holding in Top 10
1
Holding in Top 10 Change
-3
Holding in Top 10 Change %
-75%
% of All Funds
0.02%
New
21
Increased
39
Reduced
34
Closed
23
Calls
$8.67M
Puts
$4.79M
Net Calls
+$3.88M
Net Calls Change
-$13M

ALDX Hedge Fund Activity: Q4 2021 in Review

115 of the 6,498 institutional investors tracked by Wall St. Rank reported a position in Aldeyra Therapeutics (ALDX) for Q4 2021, worth a combined $147M — down 58% from $349M a quarter earlier.

Sellers outnumbered buyers: 23 funds closed out of ALDX and 21 opened new positions — a net loss of 2 holders — while 34 trimmed existing stakes and 39 added.

The largest buyer was Millennium Management, adding an estimated $9.58M. The largest seller was First Light Asset Management, exiting entirely with an estimated $26.2M sold.

  • 115 institutional investors held Aldeyra Therapeutics (ALDX) as of Q4 2021, down from 117 in Q3 2021.
  • Funds reported $147M of Aldeyra Therapeutics stock for Q4 2021, down 58% quarter-over-quarter.
  • 21 funds opened new Aldeyra Therapeutics positions in Q4 2021 and 23 closed out, a net change of -2 holders.
  • The largest Aldeyra Therapeutics buyer in Q4 2021 was Millennium Management, an estimated $9.58M added.
  • The largest Aldeyra Therapeutics seller in Q4 2021 was First Light Asset Management, an estimated $26.2M sold.

Based on aggregated 13F filings for Q4 2021.